Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Upgraded by Wolfe Research

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by research analysts at Wolfe Research to a “strong-buy” rating in a research note issued to investors on Thursday,Zacks.com reports.

Other research analysts have also recently issued research reports about the company. Guggenheim lifted their target price on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Oppenheimer cut their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. Piper Sandler cut their target price on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. BMO Capital Markets decreased their price target on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. Finally, Truist Financial cut their price objective on Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $1,099.55.

Regeneron Pharmaceuticals Stock Down 3.3 %

Shares of NASDAQ:REGN opened at $756.81 on Thursday. The stock has a market cap of $83.17 billion, a price-to-earnings ratio of 18.73, a PEG ratio of 3.04 and a beta of 0.15. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a 12-month low of $753.69 and a 12-month high of $1,211.20. The business’s 50 day moving average is $992.70 and its 200 day moving average is $1,033.92.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The trade was a 27.07 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 7.48% of the stock is owned by company insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of large investors have recently modified their holdings of REGN. Rakuten Securities Inc. lifted its stake in Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 19 shares in the last quarter. Stephens Consulting LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth $26,000. Sachetta LLC boosted its stake in Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 10 shares during the period. FSA Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals during the third quarter valued at $26,000. Finally, Crewe Advisors LLC purchased a new position in Regeneron Pharmaceuticals during the first quarter worth about $28,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.